SPORE IN BREAST CANCER

乳腺癌孢子将极大地加强和扩大UAB综合癌症中心的乳腺癌研究，重点是转译研究。其主题包括化学预防、基因治疗、靶向免疫治疗、抗血管生成、肿瘤发生的遗传机制和三苯氧胺耐药机制，这些都是国家优先考虑的领域。6个研究项目涉及跨学科研究团队，包括：1)新型维甲酸类药物的临床前/临床开发，提供UAB设计试剂的药物化学、临床前毒理学/有效性和早期临床研究；2)激素耐药：机制和逆转；2)探索诱导他莫昔芬耐药的机制和抗血管生成药物在逆转这一过程中的作用；3)新的乳腺癌癌基因GKLF的生物学和中间标记作用“将探索GKLF过表达导致的肿瘤发生机制及其作为化学预防试验的中间标记的可能性；4)“针对肿瘤血管的基因治疗”将开发针对乳腺癌血管的新型腺病毒载体，作为抗血管生成策略的介体；5)乳腺癌的多核苷酸疫苗治疗“将设计方法增强肿瘤抗原DNA疫苗在动物模型和患者中诱导抗肿瘤免疫的方法；以及6)”转移性乳腺癌的预靶向放射免疫治疗“将利用由单链抗体和链霉亲和素组成的新型融合蛋白将生物素-DOTA-放射性同位素定位到肿瘤部位。在动物模型和病人身上。这些项目将得到三个核心的支持：1)行政/生物统计学；2)组织资源和免疫病理学；3)临床试验。此外，孢子还将有一个针对乳腺癌转化性研究职业的职业发展计划(5个奖项)和一个发展研究计划(每年5-6个试点项目)。该孢子有强大的机构承诺和热情的计划与其他孢子相互作用，包括我们自己的卵巢癌孢子。这种孢子将增加科学发现，并迅速将资金转化为创新的临床试验。

The Breast Cancer SPORE will greatly strengthen and expand the breast cancer research of the UAB Comprehensive Cancer Center with an emphasis on translational research. It's themes of Chemoprevention, Gene Therapy, Targeted Immunotherapy, Anti-angiogenesis, Genetic Mechanisms of Oncogenesis, and Mechanisms of Tamoxifen Resistance are all national priority areas. Six research projects involve interdisciplinary investigative teams including: 1) "Preclinical/Clinical Development of Novel Retinoids" provides medicinal chemistry, preclinical toxicology/efficacy and early clinical study of UAB designed reagents; 2) "Hormonal Resistance: Mechanisms and Reversal" explores the mechanisms which induce Tamoxifen resistance and the role of anti- angiogenesis agents in reversal of this process; 3) "Biology and Intermediate Marker Role of a Novel Breast Cancer Oncogene, GKLF" will explore the oncogenic mechanisms resulting from GKLF over- expression and its potential as an intermediate marker in chemoprevention trials; 4) "Gene Therapy Specifically Directed at Tumor Vasculature" will develop novel adenoviral vectors targeted to breast cancer vasculature as mediators of anti-angiogenesis strategies; 5) Polynucleotide Vaccine Therapy of Breast Cancer" will design methods to enhance tumor antigen DNA vaccine induction of anti-tumor immunity in animal models and patients; and 6) "Pre-targeting Radioimmunotherapy of Metastatic Breast Cancer" which will utilize a novel fusion protein composed of single chain antibodies and streptavidin to localize Biotin-DOTA-radioactive isotopes to tumor sites. in animal models and patients. These projects will be supported by three Cores: 1) Administrative/Biostatistics; 2) Tissue Resource and Immunopathology; and 3) Clinical Trials. In addition, the SPORE will have a Career Development Program directed at careers in Breast Cancer Translational Research (5 awards) and a Developmental Research Program (5-6 pilot projects annually). The SPORE has strong institutional commitments and enthusiastic plans for interaction with other SPOREs including our own Ovarian Cancer SPORE. This SPORE will increase scientific discoveries and rapidly translate fundings into innovative clinical trials.